Repligen Corporation ($RGEN) Stock Forecast: Up 5.6% Today

What is Repligen Corporation?

Repligen Corporation (RGEN) is a biotechnology company that focuses on the development and commercialization of bioprocessing technologies for the biopharmaceutical industry. Today, RGEN experienced a strong bullish movement in the market.

Why is Repligen Corporation going up?

RGEN stock is up 5.6% on May 5, 2026 17:36

• Repligen Corporation reported impressive earnings results for the first quarter of 2026, with a significant revenue increase to $194.3 million and adjusted EPS of $0.48 per share, surpassing analyst estimates.
• The company's decision to divest its Polymem filtration business, launch a Transformation Office for margin expansion, and enter a new OEM partnership in China has likely boosted investor confidence in its growth potential.
• The increased stake in RGEN by institutional investors like Artemis Investment Management LLP and Conestoga Capital Advisors LLC further indicates positive sentiment and long-term belief in the company's performance and future prospects.
• Overall, the strong financial performance, strategic business decisions, and increased institutional investments have contributed to the bullish movement in Repligen's stock today.

RGEN Price Chart

RGEN Technical Analysis

RGEN News

Repligen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026

Repligen Corporation announced its earnings results for the first quarter ended March 31, 2026. The company reported a revenue increase to USD 194.26 million from USD 169.17 million in the prior year. Net income also rose to USD 8.33 million, resulting in basic and diluted earnings per share from continuing operations of USD 0.15.

https://www.marketscreener.com/news/repligen-corporation-reports-earnings-results-for-the-first-quarter-ended-march-31-2026-ce7f58dcdb81fe23

Repligen (NASDAQ: RGEN) posts 15% Q1 revenue growth and lifts 2026 EPS view

Repligen Corporation reported a strong first quarter for 2026, with revenue increasing by 15% to $194.3 million and adjusted diluted EPS rising to $0.48. The company also announced the divestiture of its Polymem filtration business, launched a Transformation Office to focus on margin expansion, and entered a new OEM partnership in China. For the full year 2026, Repligen reaffirmed its organic revenue growth guidance of 9%-13% and increased its adjusted EPS outlook to $1.97-$2.05.

https://www.stocktitan.net/sec-filings/RGEN/8-k-repligen-corp-reports-material-event-885c22a4181b.html

Earnings Flash (RGEN) Repligen Corporation Posts Q1 Adjusted EPS $0.48 per Share, vs. FactSet Est of $0.38

Repligen Corporation (RGEN) reported Q1 adjusted EPS of $0.48 per share, surpassing the FactSet estimate of $0.38 per share. The company also announced Q1 revenue of $194.3 million, exceeding the FactSet estimate of $192.1 million. This financial update highlights Repligen's stronger-than-expected performance for the first quarter ended March 31, 2026.

https://www.marketscreener.com/news/earnings-flash-rgen-repligen-corporation-posts-q1-adjusted-eps-0-48-per-share-vs-factset-est-of-ce7f58dcd889f224

Repligen Corporation $RGEN Holdings Raised by Artemis Investment Management LLP

Artemis Investment Management LLP increased its stake in Repligen Corporation (NASDAQ:RGEN) by 18.3% during the fourth quarter, now owning 410,369 shares valued at $67,243,000. Several other institutional investors also adjusted their holdings in the biotechnology company. Repligen's stock is currently trading at $117.20, with institutional investors owning 97.64% of the shares.

https://www.marketbeat.com/instant-alerts/filing-repligen-corporation-rgen-holdings-raised-by-artemis-investment-management-llp-2026-05-02/

Conestoga Capital Advisors LLC Buys 101,062 Shares of Repligen Corporation $RGEN

Conestoga Capital Advisors LLC has increased its stake in Repligen Corporation (NASDAQ:RGEN) by 10.6%, acquiring an additional 101,062 shares to hold a total of 1,057,975 shares, valued at approximately $173.36 million. This makes Repligen its 10th largest holding, representing about 1.88% of the company. Repligen recently reported strong quarterly earnings, beating analyst estimates with EPS of $0.49 and revenue of $197.91 million, and has a "Moderate Buy" consensus rating from analysts with an average target price of $170.25.

https://www.marketbeat.com/instant-alerts/filing-conestoga-capital-advisors-llc-buys-101062-shares-of-repligen-corporation-rgen-2026-05-01/

Trending Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 9.7% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Down 6.5% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 6.4% Today

Block Inc. ($XYZ) Stock Forecast: Up 5.1% Today

Valero Energy Corporation ($VLO) Stock Forecast: Up 5.0% Today

Upwork Inc. ($UPWK) Stock Forecast: Down 16.5% Today

Leggett & Platt Incorporated ($LEG) Stock Forecast: Down 5.9% Today

Novavax Inc. ($NVAX) Stock Forecast: Up 8.8% Today

DXC Technology Company ($DXC) Stock Forecast: Down 26.8% Today

WillScot Mobile Mini Holdings Corp. ($WSC) Stock Forecast: Up 17.2% Today

Repligen Corporation Price History

01.03.2026 - RGEN Stock was up 5.7%

• Repligen Corp (RGEN) experienced a strong bullish movement today.
• The bullish trend can be attributed to the company's impressive quarterly earnings report, surpassing expectations with $0.49 EPS and an 18.1% year-over-year revenue growth.
• Institutional ownership remains high at 97.64%, indicating continued confidence in the company's performance.
• Despite the sale of 30,070 shares by Riverbridge Partners LLC, the overall market sentiment towards Repligen remains positive, supported by its strategic positioning in the biopharma supply chain and strong financial health.

22.03.2026 - RGEN Stock was down 5.6%

• Today, Repligen Corporation (RGEN) witnessed a pronounced bearish movement in the market, likely influenced by the following factors:
• The pricing of capped notes by a financial institution linked to RGEN stock could have introduced uncertainty and potential downside risk, impacting investor sentiment.
• A recent Form 144 filing revealing a proposed resale of common shares by insiders might have triggered selling pressure and negative market perception.
• Despite its leadership in bioprocessing tools, positive analyst coverage, and a Buy rating from a prominent firm, the market movement might have been driven by profit-taking or concerns regarding valuation sensitivities in high-growth scenarios.
• Overall, a combination of these factors likely contributed to the bearish trend in RGEN stock today, notwithstanding its strong market position and growth prospects in the bioprocessing industry.

21.03.2026 - RGEN Stock was up 5.1%

• The bullish movement in Repligen Corp's stock (RGEN) today can be attributed to several factors:
• Analysts' positive views on the company's strong market position and recurring revenue model have likely boosted investor confidence.
• The initiation of coverage with a Buy rating and a price target upgrade by a notable firm highlights the company's bioprocessing strength and growth potential, further driving up the stock price.
• The opening of a new training and innovation center in the Netherlands showcases Repligen's commitment to enhancing customer support and expanding its technical capabilities, signaling future growth opportunities.
• Overall, Repligen's strategic initiatives, strong competitive position, and recent financial performance have likely contributed to the bullish market movement today.

24.03.2026 - RGEN Stock was up 5.9%

• Repligen Corporation's (RGEN) stock witnessed a positive movement despite a recent 52-week low.
• The CEO's sale of company shares under a 10b5-1 plan initially sparked concerns, but the market response appears favorable, potentially interpreted as a strategic decision.
• Favorable ratings and increased price targets from analysts, in addition to the anticipation of the upcoming financial results announcement, likely contributed to the optimistic sentiment surrounding RGEN.
• The market seems hopeful about the company's growth prospects, particularly following strong Q4 2025 earnings and the establishment of a new training center in the Netherlands, signaling global expansion.

17.02.2026 - RGEN Stock was up 5.0%

• Institutional confidence in Repligen Corporation surged as Iron Triangle Partners LP, Holocene Advisors LP, and Geneva Capital Management significantly increased their stakes in the company, reflecting strong growth prospects.
• Repligen reported stronger-than-expected Q3 earnings and revenue, surpassing quarterly estimates and providing optimistic FY2026 guidance, contributing to the bullish market movement.
• The projected boom in the Biological Product IgG Purification Medium Market, where Repligen is a key player, further fueled investor optimism and interest in the company's growth potential.
• Analysts maintaining a "Moderate Buy" consensus rating with a target price of $174.58 for Repligen amidst positive earnings reports and strategic investments also supported the bullish trend in the stock.

23.03.2026 - RGEN Stock was down 12.4%

• The CEO of Repligen Corp, Olivier Loeillot, sold 3,832 shares of the company, reducing his holding to 54,246 shares. This significant insider sell might have contributed to the bearish movement as it could signal lack of confidence in the company's future performance.
• Despite the CEO's sell-off, analysts have maintained positive ratings and raised price targets for Repligen, indicating underlying strength in the company's fundamentals.
• The upcoming earnings release on May 5, 2026, could also be a factor in the bearish movement as investors might be cautious ahead of the financial results, especially considering the recent insider selling activity.
• Overall, the combination of insider selling, upcoming earnings report, and market sentiment may have led to the bearish movement in Repligen Corp's stock today.

14.03.2026 - RGEN Stock was up 5.2%

• Repligen's stock (RGEN) saw a bullish trend after surpassing analyst expectations in Q3 earnings and revenue. This impressive financial performance likely boosted investor confidence and drove up the stock price.
• An in-depth financial analysis revealed that Filtration products significantly contribute to Repligen's overall sales, providing investors with insights into the company's revenue streams and growth opportunities.
• The market growth in the Hollow Fiber TFF Modules sector, where Repligen holds a key position, could have positively impacted RGEN's stock performance. Investors may perceive Repligen favorably within this expanding market segment, contributing to the bullish movement.

29.03.2026 - RGEN Stock was down 5.2%

• The company is expected to report a decline in earnings for the quarter, with analysts projecting a decrease in earnings per share despite higher revenues. This negative outlook likely contributed to the bearish movement in the stock.
• An insider share sale by CEO Olivier Loeillot, along with significant sales by multiple executives over the past six months, has raised concerns among investors and added to the negative sentiment surrounding the stock.
• Despite a recent gain in share price, Repligen (RGEN) has seen a significant drop over the past year, reaching a 52-week low. The company's undervaluation, coupled with insider selling and earnings uncertainties, may have intensified the selling pressure on the stock.

15.03.2026 - RGEN Stock was up 5.4%

• The bullish movement in RGEN's stock today can be attributed to the strong market trends in the bioprocessing sector and the growing demand for its specialized tools for biologics manufacturing.
• Analysts' positive views on Repligen's leadership in bioprocessing and the company's strategic acquisitions driving recurring revenue may have boosted investor confidence in its growth potential.
• The comprehensive enterprise analysis report on the Hollow Fiber TFF Modules Market, highlighting key players like Repligen Corporation, could have further emphasized the company's strong market position and growth prospects.
• The in-depth financial analysis showcasing RGEN's revenue breakdown, profitability margins, and comparison with competitors may have reassured investors of the company's solid financial performance, contributing to the bullish sentiment surrounding the stock.

31.02.2026 - RGEN Stock was up 5.8%

• Repligen Corp (RGEN) saw a significant bullish movement today.
• This upward trend may be linked to the company's impressive quarterly earnings, surpassing expectations with $0.49 EPS and an noteworthy 18.1% year-over-year revenue growth.
• Furthermore, the optimistic FY2026 EPS guidance shared by Repligen bolstered investor confidence in the company's future outlook.
• Despite institutional selling by Riverbridge Partners LLC, the substantial institutional ownership at 97.64% and analysts' "Moderate Buy" rating with a target price of $176.92 likely played a role in fostering the overall positive sentiment surrounding RGEN.

05.04.2026 - RGEN Stock was up 5.6%

• Repligen Corporation reported impressive earnings results for the first quarter of 2026, with a significant revenue increase to $194.3 million and adjusted EPS of $0.48 per share, surpassing analyst estimates.
• The company's decision to divest its Polymem filtration business, launch a Transformation Office for margin expansion, and enter a new OEM partnership in China has likely boosted investor confidence in its growth potential.
• The increased stake in RGEN by institutional investors like Artemis Investment Management LLP and Conestoga Capital Advisors LLC further indicates positive sentiment and long-term belief in the company's performance and future prospects.
• Overall, the strong financial performance, strategic business decisions, and increased institutional investments have contributed to the bullish movement in Repligen's stock today.

05.04.2026 - RGEN Stock was up 5.2%

• Today's bullish movement in Repligen's stock is driven by the positive sentiment surrounding the company, supported by institutional investors increasing their holdings and the strong quarterly earnings report. The market appears to be responding positively to the company's performance and growth potential, resulting in an increase in the stock price.